Compare CLB & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLB | CMPX |
|---|---|---|
| Founded | 1936 | 2014 |
| Country | United States | United States |
| Employees | 3300 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.0M | 408.8M |
| IPO Year | 2023 | 2020 |
| Metric | CLB | CMPX |
|---|---|---|
| Price | $10.46 | $1.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $12.50 | ★ $14.57 |
| AVG Volume (30 Days) | 410.3K | ★ 3.8M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $526,520,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | $934.41 |
| P/E Ratio | $96.64 | ★ N/A |
| Revenue Growth | ★ 0.51 | N/A |
| 52 Week Low | $9.79 | $1.13 |
| 52 Week High | $20.36 | $6.88 |
| Indicator | CLB | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 18.41 |
| Support Level | $10.58 | N/A |
| Resistance Level | $12.11 | $2.13 |
| Average True Range (ATR) | 0.48 | 0.11 |
| MACD | -0.20 | -0.11 |
| Stochastic Oscillator | 8.23 | 1.44 |
Core Laboratories Inc is a providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry, through client relationships. The company operates its business in two segments; Reservoir Description, and Production Enhancement. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services. The company generates majority of its revenue from Reservoir Description segment.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.